BioNTech co-founder 'confident' vaccine works against Indian variant of COVID-19 | Inquirer News

BioNTech co-founder ‘confident’ vaccine works against Indian variant of COVID-19

/ 06:53 PM April 28, 2021

DENVER, CO - JANUARY 30: Pharmacy technicians prepare doses of the Pfizer-BioNTech vaccine at a mass COVID-19 vaccination event on January 30, 2021 in Denver, Colorado. UCHealth, Colorado's largest healthcare provider, plans to vaccinate 10,000 seniors over 70 during the drive-up event this weekend.   Michael Ciaglo/Getty Images/AFP (Photo by Michael Ciaglo / GETTY IMAGES NORTH AMERICA / Getty Images via AFP)

Pharmacy technicians prepare doses of the Pfizer-BioNTech vaccine at a mass COVID-19 vaccination event on January 30, 2021 in Denver, Colorado. (Photo by Michael Ciaglo / GETTY IMAGES NORTH AMERICA / Getty Images via AFP)

BERLIN, Germany — BioNTech co-founder Ugur Sahin on Wednesday voiced confidence that the vaccine that his company jointly developed with Pfizer works against the Indian variant of the coronavirus.

“We are still testing the Indian variant, but the Indian variant has mutations that we have already tested for and which our vaccine works against, so I am confident,” said Sahin.

ADVERTISEMENT

“The vaccine is cleverly built and I’m convinced the bulwark will hold. And if we have to strengthen the bulwark again, then we will do it, that I’m not worried about,” he added.

FEATURED STORIES

India is facing surging new cases and deaths in the pandemic, and fears are rising that the variant could be contributing to the unfolding catastrophe.

The World Health Organization has said the B.1.617 variant of Covid-19 first found in India had as of Tuesday been detected in “at least 17 countries”.

The health agency recently listed B.1.617 — which counts several sub-lineages with slightly different mutations and characteristics — as a “variant of interest”.

But so far it has stopped short of declaring it a “variant of concern”, which would have indicated that it is more dangerous than the original version of the virus by, for instance, being more transmissible, deadly or able to dodge vaccine protections.

The BioNTech-Pfizer vaccine was the first to win authorisation in the West, and has since been deployed in dozens of countries worldwide.

Giving an update of the authorisation process in China, Sahin said approval was “very possible in July”.

ADVERTISEMENT

“We are almost through with all questions,” he said.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: BioNTech, COVID-19, Pfizer

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.